Skip to main content
Janssen is now J&J Innovative Medicine.  
 
 
 
 
MENU
VISIT JANSSEN GLOBAL

EMEA
change location▼

Search
Search

VISIT JANSSEN GLOBAL

Janssen Press release landing

Press releases

Press releases

The Media Center is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree
Cancel
NEWS CENTRE - PRESS RELEASES

LATEST PRESS RELEASES

May 01, 2024

Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease

Apr 26, 2024

Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Apr 22, 2024

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Mar 09, 2024

New data shows JNJ-2113, an investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

ALL press releases

Top Stories

Cycling for Children is back for its sixth edition on 6-8 October 2023

back to Janssen EMEA stories */ On Friday, Saturday & Sunday 6-8th of October 2023, Janssen and MedTech colleagues...

Top 8 Janssen EMEA's must-reads

back to Janssen EMEA stories At Janssen EMEA, we are not only avid readers, but we love to create new reading content...

Johnson & Johnson Makes significant Progress Towards 100% Renewable Electricity Goal with New Wind and Solar Power Purchase Agreements

back to Janssen EMEA stories As a leader in the healthcare industry, we at Johnson & Johnson know that human health...

Cycling for Children is back on 10-12 September

back to Janssen EMEA stories */ On Friday, Saturday & Sunday 10-12 September 2021 , Janssen EMEA’s flagship...

Health for Humanity report 2020 

back to Janssen EMEA stories We’ve just released our Health for Humanity report for 2020 – and set out our new Health...

New Methods of Collaboration in AI and Data Science

back to Janssen EMEA stories We’re very excited about the latest research collaboration with Janssen France between The...

ALL press releases

Transparency

Janssen EMEA is committed to increasing transparency when it comes to the relationships between pharmaceutical companies and HCPs/HCOs. Through the disclosure of transfers of value, we aim to build a better understanding of these collaborations and more recognition of their value to patient care.

 

Learn more

 

Stories about